Alquwaizani Mohammed, Buckley Leo, Adams Christopher, Fanikos John
Pharmacy Department, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115 USA.
Curr Emerg Hosp Med Rep. 2013 Apr 21;1(2):83-97. doi: 10.1007/s40138-013-0014-6. Print 2013 Jun.
Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis. Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring intervention. Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease of use and more favorable pharmacodynamic profiles. Hemorrhage is the main concerning adverse event with all anticoagulants. With their ubiquitous use, it becomes important for clinicians to have a sound understanding of anticoagulant pharmacology, dosing, and toxicity.
抗凝剂仍然是预防和治疗血栓形成的主要策略。普通肝素、低分子量肝素、磺达肝癸钠和华法林已得到广泛研究和应用,直接凝血酶抑制剂通常用于有并发症的患者或需要干预的患者。新型口服抗凝剂已从临床研发中脱颖而出,预计因其使用方便和更有利的药效学特征而取代旧有药物。出血是所有抗凝剂主要关注的不良事件。鉴于其广泛使用,临床医生充分了解抗凝药理学、剂量和毒性变得很重要。